Orchid Pharma
Orchid Pharma Share Price Chart
Orchid Pharma last traded at ₹976.00 (2026-10-13). Over the past month the stock moved -3.9%, three months the stock moved +35.2%, year the stock moved +23.8%. Its closing range over 52 weeks is ₹503.45 – ₹1,103.65, with the latest close 11.6% below the high.
Closing prices up to 2026-10-13.
About Orchid Pharma
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]
Product Segments FY24 The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Orchid Pharma reported sales of ₹304.17 crore (+15.6%) and net profit of ₹3.22 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 304.17 | 14.00 | 4.60 | 3.22 | 0.63 |
| Mar 2026 | 368.33 | 30.16 | 8.19 | 25.84 | 5.09 |
| Dec 2025 | 207.27 | 1.56 | 0.75 | -12.61 | -2.49 |
| Sep 2025 | 193.52 | -1.47 | -0.76 | -5.72 | -1.13 |
| Jun 2025 | 263.19 | -5.65 | -2.15 | -5.69 | -1.12 |
| Mar 2025 | 237.48 | 27.99 | 11.79 | 22.29 | 4.39 |
| Dec 2024 | 217.34 | 26.37 | 12.13 | 20.78 | 4.10 |
| Sep 2024 | 222.70 | 30.34 | 13.62 | 27.24 | 5.37 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +12.0% | -1.5% | +9.4% | +7.7% | -13.1% | -4.6% | +55.1% | +15.6% |
| Operating profit growth | +30.2% | -25.5% | -3.2% | -117.4% | -104.8% | -94.1% | +7.8% | – |
| Net profit growth | +37.6% | -29.4% | -32.4% | -119.4% | -121.0% | -160.7% | +15.9% | – |
| EPS growth | +37.7% | -29.3% | -32.5% | -119.3% | -121.0% | -160.7% | +15.9% | – |
| OPM % | 13.6% | 12.1% | 11.8% | -2.2% | -0.8% | 0.8% | 8.2% | 4.6% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Orchid Pharma reported sales of ₹811.00 crore (-12.0%) and net profit of ₹21.00 crore (-79.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 811.00 | 41.00 | 5.00 | 21.00 | 4.05 |
| Mar 2025 | 922.00 | 117.00 | 13.00 | 100.00 | 19.65 |
| Mar 2024 | 819.00 | 111.00 | 14.00 | 92.00 | 18.17 |
| Mar 2023 | 666.00 | 84.00 | 13.00 | 46.00 | 11.35 |
| Mar 2022 | 560.00 | 55.00 | 10.00 | -2.00 | -0.48 |
| Mar 2021 | 450.00 | 29.00 | 7.00 | -117.00 | -28.55 |
| Mar 2020 | 484.00 | -31.00 | -6.00 | -131.00 | -32.11 |
| Mar 2019 | 600.00 | -12.00 | -2.00 | 69.00 | 7.80 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -12.2% | -19.3% | -7.0% | +24.4% | +18.9% | +23.0% | +12.6% | -12.0% |
| Operating profit growth | -150.0% | – | – | +89.7% | +52.7% | +32.1% | +5.4% | -65.0% |
| Net profit growth | – | -289.9% | – | – | – | +100.0% | +8.7% | -79.0% |
| EPS growth | – | -511.7% | – | – | – | +60.1% | +8.1% | -79.4% |
| OPM % | -2.0% | -6.0% | 7.0% | 10.0% | 13.0% | 14.0% | 13.0% | 5.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Orchid Pharma.
Get Free AI Stock Analysis FREE →Latest News
-
Orchid Pharma surges 9.3% on Russia antibiotic licensing deal - Moneycontrol.com
-
Orchid Pharma shares rise 11% on Russia licensing pact for Exblifep - Moneycontrol.com
-
Orchid Pharma soars on Exblifep commercialization deal in Russia - Business Standard
-
Orchid Pharma soars on Exblifep commercialization deal in Russia - Business Standard
-
Orchid Pharma surges 9.3% on Russia antibiotic licensing deal - Moneycontrol.com
-
Orchid Pharma zooms on signing licensing and supply agreement with Pharmasyntez
-
Orchid Pharma Ltd Surges 7.14% to Day's High of Rs 834.95 — Outperforms Sector by 7.8 Percentage Points
Frequently Asked Questions
What is the share price of Orchid Pharma today?
Orchid Pharma shares were last quoted at ₹976.00 (-0.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Orchid Pharma?
Orchid Pharma has a price-to-earnings (P/E) ratio of 734.38 and a price-to-book (P/B) ratio of 4.91. The industry P/E is 53.33.
What is the 52-week high and low of Orchid Pharma?
The 52-week high of Orchid Pharma is ₹1,142.65 and the 52-week low is ₹471.30.
What is the market cap of Orchid Pharma?
The market capitalisation of Orchid Pharma is about ₹6,376.88 crore.
How did Orchid Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), Orchid Pharma reported sales of ₹304.17 crore (+15.6%) and net profit of ₹3.22 crore, compared with the same quarter last year.
Is Orchid Pharma a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Orchid Pharma has a 3-year ROE of 6.00%, 3-year profit growth of 40.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Orchid Pharma?
Promoters hold about 69.84% of Orchid Pharma.
Which sector does Orchid Pharma belong to?
Orchid Pharma belongs to the Pharmaceuticals & Drugs sector.